In defense of their patents, 10x Genomics presented a series of meritless arguments, which included disputing the publication date of a peer reviewed article. The Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) stated Parse’s evidence provided “the figurative nail in the coffin” to reject 10x Genomics’ arguments. The Final Written Decisions further noted that the patent specifications were not even focused on single cell analysis, but rather described an unrelated method.
For those who are interested in how 10x Genomics uses "meritless" lawsuits to try to suppress competition in single cell sequencing #scRNA, Parse Biosciences has now successfully invalidated all the relevant patent claims in the ongoing litigation.
www.parsebiosciences.com/news/parse-b...